GESTATIONAL DIABETES MELLITUS

✓ Medically ReviewedDISEASEID: MDBT0262🚨 TRIAGE: URGENTICD-10: O24.4

📖

Definition

CLINICAL DEFINITION

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy, in a woman who does not meet criteria for overt diabetes outside pregnancy. Diagnosis is established by a 75-g 2-hour oral glucose tolerance test (OGTT) using thresholds such as fasting plasma glucose ≥5.1 mmol/L, 1-hour ≥10.0 mmol/L, or 2-hour ≥8.5 mmol/L, with one abnormal value sufficient under the IADPSG/WHO 2013 criteria. The condition reflects inadequate pancreatic beta-cell compensation for the physiological insulin resistance of pregnancy and typically resolves after delivery, though it identifies a population at high risk for subsequent type 2 diabetes.

IN PLAIN ENGLISH

Gestational diabetes is high blood sugar that develops during pregnancy in a woman who did not have diabetes before. It happens because pregnancy hormones make the body less responsive to insulin, and the pancreas cannot keep up. It is important because it can affect the health of both the mother and the baby, but it can be managed with diet, monitoring, and sometimes medication.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Gestational diabetes mellitus is NOT the same as pre-existing type 1 or type 2 diabetes that is simply first detected during pregnancy; those are classified as pregestational diabetes (ICD-10 O24.0–O24.3) and carry different management implications. It is also not synonymous with 'overt diabetes in pregnancy', which is diagnosed when glucose values meet non-pregnant diabetes thresholds (for example, fasting ≥7.0 mmol/L or 2-hour ≥11.1 mmol/L).

🔤

Word Breakdown

gest-

='Gestational' derives from Latin 'gestatio' (a carrying, pregnancy), from 'gestare' (to carry). 'Diabetes mellitus' derives from Greek 'diabetes' (a siphon, referring to excessive urination) and Latin 'mellitus' (honey-sweet, referring to glycosuria).

Literal Meaning: Diabetes mellitus arising during gestation (pregnancy)

🏷️

Abbreviations

GDM=Gestational Diabetes Mellitus — the standard clinical abbreviation for glucose intolerance with onset or first recognition during pregnancy

OGTT=Oral Glucose Tolerance Test — the diagnostic test used to confirm GDM, typically a 75-g 2-hour load

IADPSG=International Association of Diabetes and Pregnancy Study Groups — the body whose 2010 consensus criteria for GDM are widely adopted

A1GDM=Diet-controlled gestational diabetes — GDM managed by medical nutrition therapy and lifestyle alone

A2GDM=Medication-controlled gestational diabetes — GDM requiring pharmacotherapy (insulin or an oral agent)

🔄

Synonyms & Variants

Gestational Diabetes›Pregnancy-Onset Diabetes Mellitus›

🎯

Category-Specific Context

Gestational diabetes is classified as a Disease because it is a defined metabolic condition with recognised diagnostic criteria (IADPSG/WHO 2013 75-g OGTT thresholds) and a distinct clinical course. It sits within the broader spectrum of hyperglycaemia first detected in pregnancy, which also includes pregestational diabetes and overt diabetes in pregnancy. Clinically, GDM is often sub-classified into A1GDM (diet-controlled) and A2GDM (medication-controlled) to guide management intensity and prognosis.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Antenatal ClinicObstetric WardDiabetes in Pregnancy ServiceEndocrinology Outpatient ClinicDelivery SuitePostnatal WardNeonatal Unit

USAGE & DOCUMENTATION NOTES

In clinical documentation, GDM is typically recorded as 'GDM' with the gestational age at diagnosis and the treatment modality, for example 'GDM diagnosed at 26 weeks, diet-controlled (A1GDM)' or 'GDM on insulin (A2GDM)'. The diagnostic OGTT results are documented with fasting, 1-hour, and 2-hour plasma glucose values in mmol/L. In referral letters, the key details include gestational age at diagnosis, current glycemic control (home glucose monitoring logs or HbA1c), fetal growth status, and any pharmacotherapy. Postpartum notes should record the recommendation for a 6–12 week OGTT and long-term lifestyle follow-up.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Pregnancy is characterised by a physiological decrease in insulin sensitivity, driven largely by placental hormones (including human placental lactogen, progesterone, cortisol, and prolactin) and by maternal adipose tissue changes. In a normal pregnancy, pancreatic beta cells undergo adaptive expansion and increased insulin secretion to maintain euglycaemia despite this insulin resistance. GDM arises when beta-cell compensatory capacity is insufficient to overcome the pregnancy-induced insulin resistance, resulting in maternal hyperglycaemia. This beta-cell defect is often not pregnancy-specific; in many women it reflects chronic, progressive beta-cell dysfunction that is unmasked by the metabolic stress of pregnancy. Maternal hyperglycaemia leads to fetal hyperglycaemia via placental glucose transfer, stimulating fetal pancreatic insulin secretion and fetal growth (macrosomia). The condition usually resolves after placental delivery, but the underlying beta-cell dysfunction persists and predisposes to later type 2 diabetes.

PRIMARY CAUSES

Pre-existing beta-cell dysfunction unmasked by pregnancy

Many women who develop GDM have a chronic, subclinical defect in pancreatic beta-cell function that is adequate outside pregnancy but cannot meet the increased insulin secretory demand imposed by pregnancy-related insulin resistance.

Exaggerated pregnancy-induced insulin resistance

Placental hormones and maternal adiposity reduce insulin sensitivity beyond the normal physiological range, overwhelming beta-cell compensatory capacity.

Maternal obesity and increased adiposity

Excess adipose tissue contributes to insulin resistance and lipotoxicity, impairing beta-cell function and glucose disposal.

Genetic predisposition to type 2 diabetes

Family history and genetic variants associated with beta-cell dysfunction and insulin resistance increase susceptibility to GDM.

Polycystic ovary syndrome (PCOS)

PCOS is associated with baseline insulin resistance and compensatory hyperinsulinaemia, which may reduce the reserve available to meet pregnancy demands.

Advanced maternal age

Beta-cell function and insulin sensitivity decline with age, reducing the physiological reserve needed to compensate for pregnancy-induced insulin resistance.

Previous history of GDM or delivery of a macrosomic infant

These histories identify women with underlying beta-cell dysfunction or insulin resistance that persists and recurs under the metabolic stress of a subsequent pregnancy.

💊

Drug-Induced Causes

💊 Corticosteroids (e.g., betamethasone, dexamethasone, prednisolone) ↗

Mechanism: Corticosteroids increase hepatic gluconeogenesis and induce insulin resistance, which can unmask or worsen hyperglycaemia during pregnancy.

→ When antenatal corticosteroids are indicated for fetal lung maturity, monitor blood glucose closely and consider intensified glucose-lowering therapy (often insulin) during and after administration; consult endocrinology or obstetric medicine as per local protocol.

💊 Atypical antipsychotics (e.g., olanzapine, clozapine, quetiapine) ↗

Mechanism: These agents are associated with weight gain, insulin resistance, and impaired beta-cell function, increasing the risk of hyperglycaemia.

→ Pre-pregnancy and antenatal review of antipsychotic therapy is warranted; if continued, monitor glucose tolerance and counsel on weight management. Do not stop or change antipsychotic medication without specialist psychiatric input.

💊 Beta-adrenergic agonists (e.g., salbutamol, terbutaline) ↗

Mechanism: Beta-2 agonists stimulate hepatic glycogenolysis and gluconeogenesis and may impair insulin secretion, promoting hyperglycaemia.

→ Use at the lowest effective dose when clinically indicated; in women with GDM, monitor glucose during acute tocolysis or frequent bronchodilator use and adjust glucose-lowering therapy accordingly.

🌍

Epidemiology

Prevalence:Approximately 14% of pregnancies worldwide are complicated by GDM, with wide regional variation; pooled global estimates are around 14.0%, and rates are highest in the Middle East and North Africa (approximately 27.6%) and South-East Asia (approximately 20.8%). Prevalence estimates vary substantially (roughly 5–30%) depending on the population studied and the diagnostic criteria and screening strategy used.

Age Group:GDM can occur at any reproductive age but is most common in women aged 25–35 years; risk increases with advancing maternal age, particularly at 35 years and older, while it is less common in adolescents and women under 20 years.

Sex Predilection:Female

Geographic Distribution:GDM occurs worldwide, but prevalence varies markedly by region and ethnicity. Higher rates are reported in the Middle East and North Africa (approximately 27.6%) and South-East Asia (approximately 20.8%) compared with many high-income Western populations. These differences reflect population risk factors (including obesity, genetic predisposition, and urbanisation) as well as differences in screening and diagnostic criteria.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

A woman with glucose values meeting non-pregnant diabetes thresholds (fasting ≥7.0 mmol/L or 2-hour ≥11.1 mmol/L) at first recognition in pregnancy has overt diabetes in pregnancy, not GDM; this requires prompt endocrinology or obstetric medicine involvement and a management plan beyond routine GDM care.
New-onset polyuria, polydipsia, weight loss, or ketosis in a pregnant woman with hyperglycaemia should raise concern for type 1 diabetes or diabetic ketoacidosis; urgent assessment of blood glucose, ketones, and acid–base status is required.
Severe or persistent hyperglycaemia despite lifestyle therapy and escalating pharmacotherapy, or fetal growth restriction with abnormal umbilical artery Doppler, warrants urgent specialist review for maternal and fetal well-being.

URGENT EVALUATION TRIGGERS

Blood glucose consistently above the local treatment target despite adherence to medical nutrition therapy and pharmacotherapy, particularly if accompanied by symptoms of hyperglycaemia
Symptoms or signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, Kussmaul respiration, ketotic breath) in a pregnant woman with hyperglycaemia
Severe hypoglycaemia (blood glucose <3.0 mmol/L or any level requiring third-party assistance) in a woman treated with insulin or a sulfonylurea
New hypertension, visual disturbance, severe headache, or right upper quadrant pain suggesting pre-eclampsia in a woman with GDM
Reduced fetal movements or abnormal fetal growth pattern on ultrasound

Contraindications & Precautions

SPECIAL PRECAUTIONS

Do not use a single random or fasting glucose value alone to diagnose GDM unless it meets accepted diagnostic thresholds; confirm with an OGTT where indicated.
Avoid universal pharmacological therapy without first attempting medical nutrition therapy and appropriate physical activity
unless glucose levels are markedly elevated or there is fetal compromise.
When prescribing insulin or oral glucose-lowering agents
individualise targets and monitoring to avoid maternal hypoglycaemia
especially in women with renal impairment or erratic oral intake.
During antenatal corticosteroid administration
anticipate transient worsening of hyperglycaemia and intensify glucose monitoring and therapy as needed.
At delivery
plan glucose management to maintain maternal blood glucose within the local target range (commonly 4.0–7.0 mmol/L) and prevent neonatal hypoglycaemia.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Maternal pre-eclampsia — GDM is associated with an increased risk of hypertensive disorders of pregnancy
including pre-eclampsia
Fetal macrosomia and large-for-gestational-age (LGA) — maternal hyperglycaemia drives fetal hyperinsulinaemia and excessive growth
affecting 10–20% of neonates born to women with GDM
Shoulder dystocia and birth trauma — macrosomia increases the risk of shoulder dystocia
bone fracture
and brachial plexus nerve palsy
Neonatal hypoglycaemia — fetal hyperinsulinaemia persists after delivery
causing hypoglycaemia in the neonate
Neonatal hyperbilirubinaemia and polycythaemia — associated with fetal hyperinsulinaemia and altered erythropoiesis
Cesarean delivery — increased risk of operative birth due to macrosomia and other GDM-related complications
Maternal progression to type 2 diabetes — approximately 5% of women with GDM develop type 2 diabetes within 6 months postpartum
and up to 60% within 10 years
Recurrent GDM in subsequent pregnancies — women with a history of GDM are at high risk of recurrence

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Diabetes Insipidus

Both share the word 'diabetes'; diabetes insipidus is a disorder of water balance (polyuria and polydipsia due to ADH deficiency or resistance), not glucose intolerance. Confusion can lead to inappropriate glucose-focused management.

Gestational Hypertension

Both are pregnancy-specific conditions ('gestational'); gestational hypertension is new-onset hypertension without proteinuria, whereas GDM is a glucose metabolism disorder. They can coexist (pre-eclampsia), but they are distinct diagnoses.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Pre-existing Type 2 Diabetes Mellitus

Key Distinguishing Feature: Glucose values meet non-pregnant diabetes thresholds (e.g., fasting ≥7.0 mmol/L or 2-hour ≥11.1 mmol/L) at first recognition in pregnancy, or HbA1c is in the diabetic range; these women have overt diabetes in pregnancy rather than GDM and require pre-pregnancy-style management.

Pre-existing Type 1 Diabetes Mellitus

Key Distinguishing Feature: Presence of pancreatic autoantibodies (e.g., GAD, IA-2), younger age, leaner phenotype, and a tendency to ketosis; glucose values are overtly diabetic and insulin is required from the outset.

Monogenic Diabetes (e.g., MODY)

Key Distinguishing Feature: Strong family history of young-onset diabetes, absence of autoantibodies, and sustained hyperglycaemia outside pregnancy; genetic testing may be required when GDM is atypical or persists postpartum.

Overt Diabetes in Pregnancy

Key Distinguishing Feature: Glucose values meet WHO criteria for diabetes in the non-pregnant state (fasting ≥7.0 mmol/L or 2-hour ≥11.1 mmol/L); this is not GDM and carries different prognostic and management implications.

💎

Clinical Pearls

💎

GDM is best understood as pregnancy-induced unmasking of underlying beta-cell dysfunction rather than a purely pregnancy-specific disease; this is why postpartum glucose testing is essential and why many women with GDM later develop type 2 diabetes.

💎

The diagnostic thresholds for GDM are lower than those for non-pregnant diabetes because the adverse pregnancy outcomes associated with maternal hyperglycaemia occur at glucose levels below the non-pregnant diagnostic cut-offs. Using non-pregnant thresholds in pregnancy will miss many women at risk.

💎

A1GDM (diet-controlled) and A2GDM (medication-controlled) are not just descriptive labels; A2GDM is associated with a higher risk of macrosomia, neonatal hypoglycaemia, and cesarean delivery, and generally warrants more intensive fetal surveillance.

💎

When antenatal corticosteroids are given for fetal lung maturity, expect transient hyperglycaemia; women with GDM often require intensified insulin therapy during this period, and glucose should be monitored closely for at least 48 hours after the first dose.

💎

Breastfeeding is recommended for women with GDM and may reduce the risk of progression to type 2 diabetes; postpartum care should include lactation support and a plan for a 6–12 week OGTT.

💎

Do not diagnose GDM on a single elevated fasting glucose value in early pregnancy unless it meets OGTT-based criteria; early fasting hyperglycaemia may reflect pre-existing diabetes and should prompt evaluation for overt diabetes.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"A 32-year-old woman at 26 weeks' gestation underwent a 75-g OGTT, which showed a fasting plasma glucose of 5.4 mmol/L, 1-hour glucose of 10.8 mmol/L, and 2-hour glucose of 8.9 mmol/L, confirming the diagnosis of gestational diabetes mellitus; she was commenced on medical nutrition therapy and home glucose monitoring."

IN A SOAP NOTE

S: 32-year-old G2P1 at 26 weeks' gestation referred after a 75-g OGTT showed fasting glucose 5.4 mmol/L, 1-hour 10.8 mmol/L, and 2-hour 8.9 mmol/L. She reports no polyuria, polydipsia, or visual changes. O: BP 118/74 mmHg, BMI 29 kg/m². Fundal height consistent with dates. Fetal heart rate 144 bpm. Home glucose monitoring log (fasting and 1-hour postprandial) within target on diet alone over the past week. A: Gestational diabetes mellitus, diet-controlled (A1GDM), diagnosed at 26 weeks; no features of pre-eclampsia. P: Continue medical nutrition therapy and home glucose monitoring; dietitian review in 2 weeks; repeat growth ultrasound at 32 weeks; recommend 6–12 week postpartum 75-g OGTT; patient education provided.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for newly detected hyperglycaemia in pregnancy: (1) Gestational diabetes mellitus — 75-g OGTT values meet IADPSG/WHO 2013 thresholds (fasting 5.1–6.9 mmol/L, 1-hour ≥10.0 mmol/L, or 2-hour 8.5–11.0 mmol/L) with no non-pregnant diabetes thresholds met; (2) Overt diabetes in pregnancy — fasting ≥7.0 mmol/L or 2-hour ≥11.1 mmol/L, requiring management as pre-existing diabetes; (3) Pre-existing type 1 diabetes — autoantibody-positive, ketosis-prone, often leaner, with sustained hyperglycaemia outside pregnancy; (4) Monogenic diabetes — strong family history, young onset, absence of autoantibodies, and persistence postpartum. The OGTT pattern, autoantibody status, and postpartum glucose testing are used to distinguish these.

📊

Classifications & Scoring

GRADING SYSTEM

White Classification (Modified) for Diabetes in Pregnancy

A historical prognostic classification of diabetes in pregnancy. For gestational diabetes, Class A is subdivided into A1 (diet-controlled GDM) and A2 (medication-controlled GDM). Class A1 indicates GDM managed by diet alone; Class A2 indicates GDM requiring insulin or other pharmacotherapy. Classes B through T describe pregestational diabetes by onset age, duration, and vascular complications.

View Reference ↗

📈

Prognosis

SHORT-TERM OUTCOME

With appropriate management, maternal glucose levels usually normalise after delivery and GDM resolves in the immediate postpartum period. Short-term perinatal outcomes are generally good when glycaemic targets are met, although the risk of macrosomia, neonatal hypoglycaemia, and operative delivery remains higher than in the background population. Severe perinatal complications such as death, shoulder dystocia, bone fracture, or nerve palsy are uncommon (around 3% in contemporary cohorts).

LONG-TERM PROGNOSIS

Women with GDM have a substantially increased lifetime risk of type 2 diabetes: approximately 5% develop type 2 diabetes within 6 months of birth and about 60% within 10 years. They also have an increased long-term risk of cardiovascular disease and recurrent GDM in future pregnancies. Children exposed to maternal GDM are at increased risk of obesity and impaired glucose tolerance in later life.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

O24.4

LITERATURE CITATIONS & GUIDELINES

[1]International Association of Diabetes and Pregnancy Study Groups Consensus Panel; Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-682.

[2]World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: WHO; 2013.

[3]National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline NG3. 2015 (updated 2020).

[4]American College of Obstetricians and Gynecologists. Gestational diabetes mellitus. ACOG Practice Bulletin No. 190. Obstet Gynecol. 2018;131(2):e49-e64.

[5]Buchanan TA, Xiang AH, Page KA, Watanabe RM. What Is Gestational Diabetes—Really? Diabetes. 2025;74(7):1037-1046.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.